奥利司他与急性肾损伤：953例患者的分析 - Suppr

Suppr

超能文献

Orlistat and acute kidney injury: an analysis of 953 patients.

作者信息

Weir Matthew A, Beyea Michael M, Gomes Tara, Juurlink David N, Mamdani Muhammad, Blake Peter G, Wald Ron, Garg Amit X

出版信息

Arch Intern Med. 2011 Apr 11;171(7):703-4. doi: 10.1001/archinternmed.2011.103.

DOI:10.1001/archinternmed.2011.103

PMID:21482850

Abstract

摘要

相似文献

Orlistat and acute kidney injury: an analysis of 953 patients.

Arch Intern Med. 2011 Apr 11;171(7):703-4. doi: 10.1001/archinternmed.2011.103.

Acute oxalate nephropathy.

Clin Med (Lond). 2012 Dec;12(6):600. doi: 10.7861/clinmedicine.12-6-600.

Orlistat, an under-recognised cause of progressive renal impairment.

Nephrol Dial Transplant. 2013 Nov;28 Suppl 4:iv172-4. doi: 10.1093/ndt/gft066. Epub 2013 Sep 18.

Acute pancreatitis following orlistat therapy: report of two cases.

JOP. 2010 Jan 8;11(1):61-3.

Rapidly progressive renal failure associated with successful pharmacotherapy for obesity.

Nephrol Dial Transplant. 2007 Feb;22(2):621-3. doi: 10.1093/ndt/gfl684. Epub 2006 Nov 22.

An unusual complication of treatment with orlistat.

Clin Nephrol. 2009 Apr;71(4):430-2. doi: 10.5414/cnp71430.

Orlistat and calcium oxalate crystalluria: an association that needs consideration.

Ren Fail. 2010;32(8):1019-21. doi: 10.3109/0886022X.2010.501929.

Orlistat without a prescription: drug interactions, pancreatitis and kidney disorders.

Prescrire Int. 2010 Jun;19(107):125.

Depression induced by orlistat (Xenical).

Can J Psychiatry. 2000 Feb;45(1):87.

Acute oxalate nephropathy secondary to orlistat-induced enteric hyperoxaluria.

Nephrology (Carlton). 2013 Mar;18(3):241-2. doi: 10.1111/j.1440-1797.2012.01649.x.

引用本文的文献

Endoscopic Sleeve Gastroplasty for Obesity Management Should Also Be a Consideration in Patients Unsuitable for Anti-obesity Medications.

Obes Surg. 2025 Mar;35(3):1185-1187. doi: 10.1007/s11695-025-07717-8. Epub 2025 Jan 29.

Metabolism at the crossroads of inflammation and fibrosis in chronic kidney disease.

Nat Rev Nephrol. 2025 Jan;21(1):39-56. doi: 10.1038/s41581-024-00889-z. Epub 2024 Sep 17.

Obesity medications: A narrative review of current and emerging agents.

Osteoarthr Cartil Open. 2024 Apr 25;6(2):100472. doi: 10.1016/j.ocarto.2024.100472. eCollection 2024 Jun.

Update on Pediatric Anti-obesity Medications-Current Landscape and Approach to Prescribing.

Curr Obes Rep. 2024 Jun;13(2):295-312. doi: 10.1007/s13679-024-00566-z. Epub 2024 Apr 30.

A nanoemulsion targeting adipose hypertrophy and hyperplasia shows anti-obesity efficiency in female mice.

Nat Commun. 2024 Jan 2;15(1):72. doi: 10.1038/s41467-023-44416-3.

An efficient online peak detection algorithm for synchronized intestinal electrical stimulation and its application for treating diabetes.

Med Biol Eng Comput. 2023 Sep;61(9):2317-2327. doi: 10.1007/s11517-023-02832-z. Epub 2023 Apr 15.

New Incretin Combination Treatments under Investigation in Obesity and Metabolism: A Systematic Review.

Pharmaceuticals (Basel). 2021 Aug 28;14(9):869. doi: 10.3390/ph14090869.

Phytohemagglutinin ameliorates HFD-induced obesity by increasing energy expenditure.

J Mol Endocrinol. 2021 Jun 17;67(1):1-14. doi: 10.1530/JME-20-0349.

Management of Obesity in Adults with CKD.

J Am Soc Nephrol. 2021 Apr;32(4):777-790. doi: 10.1681/ASN.2020101472. Epub 2021 Feb 18.

Antiobesity effects of seedlac and shellac in rats fed with a high-fat diet.

Res Pharm Sci. 2020 Feb 20;15(1):57-65. doi: 10.4103/1735-5362.278715. eCollection 2020 Feb.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Orlistat and acute kidney injury: an analysis of 953 patients.

Arch Intern Med. 2011 Apr 11;171(7):703-4. doi: 10.1001/archinternmed.2011.103.

Acute oxalate nephropathy.

Clin Med (Lond). 2012 Dec;12(6):600. doi: 10.7861/clinmedicine.12-6-600.

Orlistat, an under-recognised cause of progressive renal impairment.

Nephrol Dial Transplant. 2013 Nov;28 Suppl 4:iv172-4. doi: 10.1093/ndt/gft066. Epub 2013 Sep 18.

Acute pancreatitis following orlistat therapy: report of two cases.

JOP. 2010 Jan 8;11(1):61-3.

Rapidly progressive renal failure associated with successful pharmacotherapy for obesity.

Nephrol Dial Transplant. 2007 Feb;22(2):621-3. doi: 10.1093/ndt/gfl684. Epub 2006 Nov 22.

An unusual complication of treatment with orlistat.

Clin Nephrol. 2009 Apr;71(4):430-2. doi: 10.5414/cnp71430.

Orlistat and calcium oxalate crystalluria: an association that needs consideration.

Ren Fail. 2010;32(8):1019-21. doi: 10.3109/0886022X.2010.501929.

Orlistat without a prescription: drug interactions, pancreatitis and kidney disorders.

Prescrire Int. 2010 Jun;19(107):125.

Depression induced by orlistat (Xenical).

Can J Psychiatry. 2000 Feb;45(1):87.

Acute oxalate nephropathy secondary to orlistat-induced enteric hyperoxaluria.

Nephrology (Carlton). 2013 Mar;18(3):241-2. doi: 10.1111/j.1440-1797.2012.01649.x.

引用本文的文献

Endoscopic Sleeve Gastroplasty for Obesity Management Should Also Be a Consideration in Patients Unsuitable for Anti-obesity Medications.

Obes Surg. 2025 Mar;35(3):1185-1187. doi: 10.1007/s11695-025-07717-8. Epub 2025 Jan 29.

Metabolism at the crossroads of inflammation and fibrosis in chronic kidney disease.

Nat Rev Nephrol. 2025 Jan;21(1):39-56. doi: 10.1038/s41581-024-00889-z. Epub 2024 Sep 17.

Obesity medications: A narrative review of current and emerging agents.

Osteoarthr Cartil Open. 2024 Apr 25;6(2):100472. doi: 10.1016/j.ocarto.2024.100472. eCollection 2024 Jun.

Update on Pediatric Anti-obesity Medications-Current Landscape and Approach to Prescribing.

Curr Obes Rep. 2024 Jun;13(2):295-312. doi: 10.1007/s13679-024-00566-z. Epub 2024 Apr 30.

A nanoemulsion targeting adipose hypertrophy and hyperplasia shows anti-obesity efficiency in female mice.

Nat Commun. 2024 Jan 2;15(1):72. doi: 10.1038/s41467-023-44416-3.

An efficient online peak detection algorithm for synchronized intestinal electrical stimulation and its application for treating diabetes.

Med Biol Eng Comput. 2023 Sep;61(9):2317-2327. doi: 10.1007/s11517-023-02832-z. Epub 2023 Apr 15.

New Incretin Combination Treatments under Investigation in Obesity and Metabolism: A Systematic Review.

Pharmaceuticals (Basel). 2021 Aug 28;14(9):869. doi: 10.3390/ph14090869.

Phytohemagglutinin ameliorates HFD-induced obesity by increasing energy expenditure.

J Mol Endocrinol. 2021 Jun 17;67(1):1-14. doi: 10.1530/JME-20-0349.

Management of Obesity in Adults with CKD.

J Am Soc Nephrol. 2021 Apr;32(4):777-790. doi: 10.1681/ASN.2020101472. Epub 2021 Feb 18.

Antiobesity effects of seedlac and shellac in rats fed with a high-fat diet.

Res Pharm Sci. 2020 Feb 20;15(1):57-65. doi: 10.4103/1735-5362.278715. eCollection 2020 Feb.